In today’s briefing:
- Kelun-Biotech (科伦博泰) IPO: Fairly Valued at Best
- MariMed, Inc. – Management Series Report Cannabis
Kelun-Biotech (科伦博泰) IPO: Fairly Valued at Best
- Kelun-Biotech is a China-based integrated innovative biopharmaceutical company. The company launched a deal to raise up to US$200m via a Hong Kong listing.
- In our previous note, we looked at the company’s product lines and provided a brief overview on the company’s valuation.
- In this note, we provide an update for the book building. We provide our quick thoughts on the valuation and deal dynamics.
MariMed, Inc. – Management Series Report Cannabis
- MariMed is a multi-state operator (MSO) in the US cannabis industry.
- It has a national footprint spanning six states: Illinois, Massachusetts, Maryland, Delaware, Ohio, and Missouri.
- MariMed focuses on limited-license markets and strives to be vertically integrated wherever possible.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
